Abstract:Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI), hospitalization, and mortality in infants and young children globally. The greatest burden of severe disease and mortality occurs in low‐middle income countries (LMICs), with large and vulnerable childhood populations. The highest rates of RSV‐hospitalization occur in healthy‐term infants under 3 months of age. Preterm infants, children with chronic lung disease of prematurity, Down's syndrome, congenital heart disease, or immunodeficiency also have a higher risk of severe RSV‐LRTI. Early‐life RSV‐LRTI has also been associated with chronic sequelae, including recurrent LRTI, recurrent wheezing, asthma, and lung function impairment. A RSV pre‐fusion (F) maternal vaccine and long‐acting monoclonal antibody (nirsevimab) have been licensed for the prevention of RSV‐LRTI in infants and young children. Studies show high efficacy and effectiveness particularly for preventing severe RSV‐LRTI. Maternal RSV vaccine given at 24–36 weeks of pregnancy was effective in preventing RSV medically attended LRTI and severe RSV‐LRTI through 6 months after birth in a phase 3 study conducted in 18 countries over two RSV seasons. Vaccination was safe with no significant difference in adverse events between infants born to mothers who received RSV preF vaccine compared to placebo. A numerical imbalance in preterm births that occurred predominantly in South Africa, unrelated to vaccine timing or gestational age at vaccination and unassociated with mortality, coincided with COVID‐19 delta and omicron waves. Nirsevimab, given as a single dose prior or during the RSV season, had high efficacy in preventing RSV‐LRTI hospitalization in infants in preterm and in full‐term infants, as well as in young children with underlying conditions through 150 days post administration in phase 2 and 3 trials. High effectiveness against hospitalization or severe disease in infants and in at‐risk children up to 2 years of age has also been reported in several countries where implementation has occurred. RSV‐LRTI is now a preventable disease in infants and young children. Rapid implementation of these highly effective interventions has occurred in many high‐income countries, but access remains very limited in LMICs. Access to such RSV preventive interventions is urgently needed for all children to strengthen child health and promote global equity.

Electrospinning Synthesis and Photoluminescence Properties of One-Dimensional SiO 2 :Tb 3+ Nanofibers and Nanobelts

Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date

Updates on respiratory syncytial virus prophylaxis: the past, present and future

Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus

Comprehensive review of Respiratory Syncytial Virus (RSV) Vaccination: Progress, Challenges, and Future Direction

Respiratory syncytial virus infection and novel interventions

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children

Best practice in the prevention and management of paediatric respiratory syncytial virus infection

Current State of Respiratory Syncytial Virus Disease and Management

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies

The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis

The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness

Expert Consensus on the Diagnosis, Treatment, and Prevention of Respiratory Syncytial Virus Infections in Children

New advances in RSV: Is prevention attainable?

Fog fever and precipitins to micro-organisms of mouldy hay.

Re-thinking the biology of essential tremor: from models to morphology.

RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

Respiratory Syncytial Virus Prevention: A New Era of Vaccines

Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates